AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

Findings From Tezspire® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS® (avacopan) Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts ...